We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

184 hedge funds and large institutions have $960M invested in ARS Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

90% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 21

28% more capital invested

Capital invested by funds: $752M → $960M (+$207M)

12% more funds holding

Funds holding: 165 → 184 (+19)

4.37% more ownership

Funds ownership: 73.37% → 77.73% (+4.4%)

5% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 55

41% less call options, than puts

Call options by funds: $2.67M | Put options by funds: $4.54M

Holders
184
Holders Change
+19
Holders Change %
+11.52%
% of All Funds
2.47%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
40
Increased
58
Reduced
55
Closed
21
Calls
$2.67M
Puts
$4.54M
Net Calls
-$1.88M
Net Calls Change
-$910K

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$15.8M
2
CAM
Cormorant Asset Management
Massachusetts
+$13.2M
3
RCMNY
Rubric Capital Management (New York)
New York
+$12.4M
4
Aberdeen Group
Aberdeen Group
United Kingdom
+$12.1M
5
LCS
Levin Capital Strategies
New York
+$8.39M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$11.6M
2
State Street
State Street
Massachusetts
-$8.65M
3
WP
Woodline Partners
California
-$6.24M
4
UBS Group
UBS Group
Switzerland
-$5.07M
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$3.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
51
Barclays
United Kingdom
$1.66M -$315K -26,145 -17%
Wellington Management Group
52
Wellington Management Group
Massachusetts
$1.66M -$379K -31,476 -19%
EIP
53
Epoch Investment Partners
New York
$1.5M +$1.43M +118,982 New
QOP
54
Quinn Opportunity Partners
Virginia
$1.4M +$1.34M +111,628 New
Ameriprise
55
Ameriprise
Minnesota
$1.31M +$418K +34,734 +50%
TI
56
Trexquant Investment
Connecticut
$1.27M +$532K +44,206 +78%
SAM
57
Sectoral Asset Management
Quebec, Canada
$1.26M -$69.8K -5,802 -5%
LCM
58
Legato Capital Management
California
$1.22M +$904K +75,130 +350%
DCM
59
DAFNA Capital Management
California
$1.2M +$78.2K +6,500 +7%
Citigroup
60
Citigroup
New York
$1.2M -$65.8K -5,473 -5%
SEI Investments
61
SEI Investments
Pennsylvania
$1.2M -$159K -13,239 -12%
American Century Companies
62
American Century Companies
Missouri
$1.17M -$4.7K -391 -0.4%
Cambridge Investment Research Advisors
63
Cambridge Investment Research Advisors
Iowa
$1.1M – – –
VFIC
64
Valley Forge Investment Consultants
Pennsylvania
$1.05M – – –
Squarepoint
65
Squarepoint
New York
$966K +$626K +52,047 +210%
Swiss National Bank
66
Swiss National Bank
Switzerland
$952K – – –
Rafferty Asset Management
67
Rafferty Asset Management
New York
$948K -$783K -65,050 -46%
MGM
68
Miura Global Management
New York
$944K -$1.14M -95,000 -56%
New York State Common Retirement Fund
69
New York State Common Retirement Fund
New York
$915K +$438K +36,411 +100%
RhumbLine Advisers
70
RhumbLine Advisers
Massachusetts
$878K +$55.4K +4,603 +7%
AIA
71
AssuredPartners Investment Advisors
Florida
$869K +$475K +39,500 +133%
VOYA Investment Management
72
VOYA Investment Management
Georgia
$827K -$18.7K -1,554 -2%
CM
73
CastleKnight Management
New York
$821K +$786K +65,300 New
KCM
74
Kodai Capital Management
Illinois
$756K +$723K +60,111 New
Wells Fargo
75
Wells Fargo
California
$750K +$216K +17,946 +43%
1 2
3
4 5

SPRY Hedge Fund Activity: Q1 2025 in Review

184 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2025, worth a combined $960M — up 28% from $752M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new SPRY positions and 21 closed out — a net gain of 19 holders — while 58 added to existing stakes and 55 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $15.8M. The largest seller was Alyeska Investment Group, cutting an estimated $11.6M.

  • 184 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2025, up from 165 in Q4 2024.
  • Funds reported $960M of ARS Pharmaceuticals stock for Q1 2025, up 28% quarter-over-quarter.
  • 40 funds opened new ARS Pharmaceuticals positions in Q1 2025 and 21 closed out, a net change of +19 holders.
  • The largest ARS Pharmaceuticals buyer in Q1 2025 was MPM BioImpact, an estimated $15.8M added.
  • The largest ARS Pharmaceuticals seller in Q1 2025 was Alyeska Investment Group, an estimated $11.6M sold.

Based on aggregated 13F filings for Q1 2025.